These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33592876)

  • 1. Sunitinib-associated hyperammonemic encephalopathy successfully managed with higher intensity conventional hemodialysis: A case report.
    Haroon S; Ko S; Wong A; Tan PS; Lee E; Lau T
    Medicine (Baltimore); 2021 Feb; 100(5):e24313. PubMed ID: 33592876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Rare Case of Sunitinib-Induced Hyperammonemic Encephalopathy and Hypothyroidism in Metastatic Renal Cell Carcinoma.
    Pilanc KN; Elbüken F; Ordu Ç; Köksal G; Tekelioğlu MH; Okutur K; Göksel S; Köksal Ü; Akçal T; Tecimer C
    Am J Ther; 2016; 23(2):e583-7. PubMed ID: 24901901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib-associated hyperammonemic encephalopathy.
    Lipe DN; Hoxha B; Sahai SK
    Am J Emerg Med; 2021 Aug; 46():282-283. PubMed ID: 32811710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute sunitinib neurotoxicity.
    Gulmez A; Dikilitas M; Elkiran ET; Harputluoglu H
    Cancer Treat Res Commun; 2021; 27():100366. PubMed ID: 33812180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
    Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK
    Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
    Park CY
    Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
    Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
    BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib therapy as a cause of diffuse digestive tract hemorrhage in end-stage renal disease patient.
    Taki Y; Imai N; Kojima S; Kaneshiro N; Shibagaki Y
    Saudi J Kidney Dis Transpl; 2018; 29(2):483-484. PubMed ID: 29657229
    [No Abstract]   [Full Text] [Related]  

  • 9. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
    Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib.
    Kongsuphon N; Soukavanitch M; Teeraaumpornpunt N; Konmun J; Ativitavas T; Ngamphaiboon N
    J Gastrointest Cancer; 2019 Sep; 50(3):601-603. PubMed ID: 29411249
    [No Abstract]   [Full Text] [Related]  

  • 11. Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial.
    Mouillet G; Paillard MJ; Maurina T; Vernerey D; Nguyen Tan Hon T; Almotlak H; Stein U; Calcagno F; Berthod D; Robert E; Meurisse A; Thiery-Vuillemin A
    Trials; 2018 Apr; 19(1):221. PubMed ID: 29650037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis D reactivation in a patient with metastatic renal cell carcinoma receiving sunitinib therapy.
    Akar E; Yücel MH; Şahin T; Tural D
    Tumori; 2019 Dec; 105(6):NP72-NP74. PubMed ID: 30935288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of sunitinib concentration and clinical outcome in patients with metastatic renal cell carcinoma treated with a 2-week-on and 1-week-off schedule.
    Ito T; Yamamoto K; Furukawa J; Harada K; Fujisawa M; Omura T; Yano I
    J Clin Pharm Ther; 2022 Jan; 47(1):81-88. PubMed ID: 34669974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
    Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS
    Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe toxicity induced by accumulation of active sunitinib metabolite in a Japanese patient with renal cell carcinoma: a case report.
    Takasaki S; Kikuchi M; Kawasaki Y; Ito A; Arai Y; Yamaguchi H; Mano N
    J Med Case Rep; 2017 Feb; 11(1):28. PubMed ID: 28143610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
    Wong MK; Jarkowski A
    Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma.
    Ishihara H; Fukuda H; Tachibana H; Yoshida K; Kobayashi H; Takagi T; Iizuka J; Ishida H; Nagashima Y; Kondo T; Tanabe K
    Clin Exp Nephrol; 2021 Jun; 25(6):674-682. PubMed ID: 33641007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate.
    Lim TJ; Lee JH; Chang SG; Lee CH; Min GE; Yoo KH; Jeon SH
    Urol Int; 2010; 85(4):475-8. PubMed ID: 20975258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of sunitinib in hemodialysis.
    Izzedine H; Etienne-Grimaldi MC; Renée N; Vignot S; Milano G
    Ann Oncol; 2009 Jan; 20(1):190-2. PubMed ID: 18801884
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe neurological symptoms in a patient with advanced renal cell carcinoma treated with sunitinib.
    Duchnowska R; Miciuk B; Bodnar L; Waśniewski L; Szczylik C
    J Oncol Pharm Pract; 2013 Jun; 19(2):186-9. PubMed ID: 23037634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.